RxDoctor Payments Data

Jamie Nguyen, MD

Infectious Disease · Marrero, LANPI 1093033458

Payments from drug & device makers

$251in general payments, 2019–2025

Across 16 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$51
  • Johnson & Johnson$50
  • Theratechnologies Inc.$38
  • Novo Nordisk$34
  • Merck$28
  • Viiv Healthcare Company$17
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$251100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$251 in reported general payments places this provider in the 30th percentile of 105 infectious disease providers in Louisiana.

See all infectious disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,002
Medicare patients
100
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala27$114,280
TivicayDolutegravir Sodium12$26,547
DescovyEmtricitabine/Tenofov Alafenam11$23,741
Daptomycin16$19,596
Rifabutin23$10,555
Vancomycin Hcl41$10,495
ErtapenemErtapenem Sodium15$8,027
Ethambutol Hcl94$6,022
Rifampin79$5,637
Meropenem20$4,055
Fluconazole33$3,289
Cefepime Hcl14$2,608
Cefazolin Sodium27$1,898
Azithromycin94$1,755
Doxycycline Hyclate37$1,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$16$138,02138 claims
Viiv Healthcare CompanyTivicay$17$26,54712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 105 infectious disease providers in Louisiana.

Other infectious disease in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →